Gene therapy for esophageal carcinoma: The use of an explant model to test adenoviral vectors ex vivo

Willem A. Marsman, Christianne J. Buskens, John G. Wesseling, G. Johan A Offerhaus, Jacques J G H M Bergman, Guido N J Tytgat, J. Jan B Van Lanschot, Piter J. Bosma

Research output: Contribution to journalArticlepeer-review

Abstract

Adenoviral gene therapy might be a promising therapeutic strategy for esophageal carcinoma. However, adenoviral transduction efficacy in vivo is still limited. This efficacy can be improved by the insertion of an Arg-Gly-Asp (RGD) peptide in the HI-loop of the viral fiber knob. Indeed in established esophageal cell lines, we observed an up to six-fold improved transduction using the RGD-targeted adenovirus. Established cell lines, however, are easily transformed and do not represent the more complex in vivo histology and anatomy. Therefore, we set up an esophageal explant model using esophageal biopsies from patients. Viability is a limiting factor for this system. Cultured squamous epithelium, intestinal metaplasia and squamous cell carcinoma had a sufficient viability to study adenoviral transduction. Viability of the cultured adenocarcinoma biopsies was poor. Adenoviral transduction in the explant model was poor and was localized in particular cells. The transduction of the nontargeted and RGD-targeted adenovirus was similar in localization and efficacy. In conclusion, we established an esophageal explant system to test the transduction of adenoviral vectors ex vivo. The transduction was limited and localized in specific cells. RGD-targeted adenovirus did not show an improved transduction in this system.

Original languageEnglish (US)
Pages (from-to)289-296
Number of pages8
JournalCancer Gene Therapy
Volume11
Issue number4
DOIs
StatePublished - Apr 2004
Externally publishedYes

Keywords

  • Adenovirus
  • Barrett esophagus
  • Esophageal cancer
  • Explant
  • RGD

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Fingerprint Dive into the research topics of 'Gene therapy for esophageal carcinoma: The use of an explant model to test adenoviral vectors ex vivo'. Together they form a unique fingerprint.

Cite this